================================================================================
QUICK PATIENT-STUDY MATCHING REPORT
================================================================================
Generated: 2025-07-17 10:46:03
Total patients: 5

PATIENT 1
----------------------------------------
Diagnosis: NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)
Koloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G1 NET.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

07/2015 Resektion der Lebermetastasen in Segment VI und Ablation der Läsion in Segment VIII. Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.
01/2017 V.a. neue Lebermetastase
02/2017 Start Somatoline
02/2018 CT Abdomen: stable disease
03/2019 CT Abdomen: V.a. gering progrediente Lebermetastasen. 
Relevant studies found: 20

  1. A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
     NCT ID: NCT00428220
     Phase: NA | Status: COMPLETED
     Relevance: 29 - NET condition match; Small intestine NET match; Liver metastases match; Completed study
     URL: https://clinicaltrials.gov/study/NCT00428220

  2. A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
     NCT ID: NCT01578239
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 28 - NET condition match; Small intestine NET match; Completed study; PHASE3 study; 4 publications
     URL: https://clinicaltrials.gov/study/NCT01578239

  3. Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
     NCT ID: NCT03736720
     Phase: PHASE2 | Status: TERMINATED
     Relevance: 27 - NET condition match; Small intestine NET match; Liver metastases match; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT03736720

  4. Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
     NCT ID: NCT00171873
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 26 - NET condition match; Small intestine NET match; Completed study; PHASE3 study
     URL: https://clinicaltrials.gov/study/NCT00171873

  5. AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
     NCT ID: NCT00427349
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 26 - NET condition match; Small intestine NET match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00427349

  6. Phase 2 Study of ONC201 in Neuroendocrine Tumors
     NCT ID: NCT03034200
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 26 - NET condition match; Liver metastases match; Completed study; PHASE2 study; 8 publications
     URL: https://clinicaltrials.gov/study/NCT03034200

  7. Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
     NCT ID: NCT01967537
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 26 - NET condition match; Liver metastases match; Completed study; PHASE2 study; 3 publications
     URL: https://clinicaltrials.gov/study/NCT01967537

  8. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
     NCT ID: NCT03037385
     Phase: PHASE1 | Status: COMPLETED
     Relevance: 25 - NET condition match; Small intestine NET match; Completed study; 4 publications
     URL: https://clinicaltrials.gov/study/NCT03037385

  9. RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
     NCT ID: NCT00113360
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 24 - NET condition match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00113360

  10. A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
     NCT ID: NCT02402062
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 24 - NET condition match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT02402062


================================================================================

PATIENT 2
----------------------------------------
Diagnosis: NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)
Koloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G3 NET, Ki67 48%.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.
Relevant studies found: 20

  1. A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
     NCT ID: NCT00428220
     Phase: NA | Status: COMPLETED
     Relevance: 29 - NET condition match; Small intestine NET match; Liver metastases match; Completed study
     URL: https://clinicaltrials.gov/study/NCT00428220

  2. A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
     NCT ID: NCT01578239
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 28 - NET condition match; Small intestine NET match; Completed study; PHASE3 study; 4 publications
     URL: https://clinicaltrials.gov/study/NCT01578239

  3. Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
     NCT ID: NCT03736720
     Phase: PHASE2 | Status: TERMINATED
     Relevance: 27 - NET condition match; Small intestine NET match; Liver metastases match; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT03736720

  4. Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
     NCT ID: NCT00171873
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 26 - NET condition match; Small intestine NET match; Completed study; PHASE3 study
     URL: https://clinicaltrials.gov/study/NCT00171873

  5. AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
     NCT ID: NCT00427349
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 26 - NET condition match; Small intestine NET match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00427349

  6. Phase 2 Study of ONC201 in Neuroendocrine Tumors
     NCT ID: NCT03034200
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 26 - NET condition match; Liver metastases match; Completed study; PHASE2 study; 8 publications
     URL: https://clinicaltrials.gov/study/NCT03034200

  7. Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
     NCT ID: NCT01967537
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 26 - NET condition match; Liver metastases match; Completed study; PHASE2 study; 3 publications
     URL: https://clinicaltrials.gov/study/NCT01967537

  8. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
     NCT ID: NCT03037385
     Phase: PHASE1 | Status: COMPLETED
     Relevance: 25 - NET condition match; Small intestine NET match; Completed study; 4 publications
     URL: https://clinicaltrials.gov/study/NCT03037385

  9. RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
     NCT ID: NCT00113360
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 24 - NET condition match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00113360

  10. A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
     NCT ID: NCT02402062
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 24 - NET condition match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT02402062


================================================================================

PATIENT 3
----------------------------------------
Diagnosis: NET des Dünndarms mit Lymphknoten und Lebermetastasen (ED 2015)
Koloskopie bei unklaren abdominellen Beschwerden 06/2015: Tumor im Ileum 25 cm oberhalb der Ileozökalklappe. G2 NET.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Ileums 40 x 40 x 70 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

07/2015 DOTATOC PET: geringe Speicherung der Leberläsionen.
07/2015 Hemicolektomie rechts und Ileumteilresektion mit Lymphadenektomie.
Relevant studies found: 20

  1. A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
     NCT ID: NCT00428220
     Phase: NA | Status: COMPLETED
     Relevance: 29 - NET condition match; Small intestine NET match; Liver metastases match; Completed study
     URL: https://clinicaltrials.gov/study/NCT00428220

  2. A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
     NCT ID: NCT01578239
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 28 - NET condition match; Small intestine NET match; Completed study; PHASE3 study; 4 publications
     URL: https://clinicaltrials.gov/study/NCT01578239

  3. Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
     NCT ID: NCT03736720
     Phase: PHASE2 | Status: TERMINATED
     Relevance: 27 - NET condition match; Small intestine NET match; Liver metastases match; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT03736720

  4. Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
     NCT ID: NCT00171873
     Phase: PHASE3 | Status: COMPLETED
     Relevance: 26 - NET condition match; Small intestine NET match; Completed study; PHASE3 study
     URL: https://clinicaltrials.gov/study/NCT00171873

  5. AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
     NCT ID: NCT00427349
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 26 - NET condition match; Small intestine NET match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00427349

  6. Phase 2 Study of ONC201 in Neuroendocrine Tumors
     NCT ID: NCT03034200
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 26 - NET condition match; Liver metastases match; Completed study; PHASE2 study; 8 publications
     URL: https://clinicaltrials.gov/study/NCT03034200

  7. Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
     NCT ID: NCT01967537
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 26 - NET condition match; Liver metastases match; Completed study; PHASE2 study; 3 publications
     URL: https://clinicaltrials.gov/study/NCT01967537

  8. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
     NCT ID: NCT03037385
     Phase: PHASE1 | Status: COMPLETED
     Relevance: 25 - NET condition match; Small intestine NET match; Completed study; 4 publications
     URL: https://clinicaltrials.gov/study/NCT03037385

  9. RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
     NCT ID: NCT00113360
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 24 - NET condition match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00113360

  10. A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
     NCT ID: NCT02402062
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 24 - NET condition match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT02402062


================================================================================

PATIENT 4
----------------------------------------
Diagnosis: NET des Pankreas mit Lymphknoten und Lebermetastasen (ED 2015)
CT bei unklaren abdominellen Beschwerden 06/2015: Tumor im Pankreas. G2 NET.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Pankreas 20 x 40 x 30 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

08/2015 Start Somatuline
06/2016 DOTATOC PET: Progress der Lebermetastasen, starke Speicherung der Leberläsionen.
Relevant studies found: 20

  1. RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
     NCT ID: NCT00113360
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 32 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00113360

  2. A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
     NCT ID: NCT02402062
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 32 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT02402062

  3. Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
     NCT ID: NCT01010126
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 32 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT01010126

  4. Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
     NCT ID: NCT01169649
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 32 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT01169649

  5. Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
     NCT ID: NCT00454363
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 32 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00454363

  6. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
     NCT ID: NCT03375320
     Phase: PHASE3 | Status: ACTIVE_NOT_RECRUITING
     Relevance: 29 - NET condition match; Pancreatic NET match; Liver metastases match; Active study; PHASE3 study
     URL: https://clinicaltrials.gov/study/NCT03375320

  7. A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
     NCT ID: NCT00428220
     Phase: NA | Status: COMPLETED
     Relevance: 29 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study
     URL: https://clinicaltrials.gov/study/NCT00428220

  8. OPALINE : A Study Of Morbidity And Mortality At 2 Years
     NCT ID: NCT02264665
     Phase: N/A | Status: COMPLETED
     Relevance: 29 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study
     URL: https://clinicaltrials.gov/study/NCT02264665

  9. The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
     NCT ID: NCT02282059
     Phase: N/A | Status: COMPLETED
     Relevance: 29 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study
     URL: https://clinicaltrials.gov/study/NCT02282059

  10. A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
     NCT ID: NCT02288377
     Phase: PHASE2 | Status: TERMINATED
     Relevance: 29 - NET condition match; Pancreatic NET match; Liver metastases match; PHASE2 study; 3 publications
     URL: https://clinicaltrials.gov/study/NCT02288377


================================================================================

PATIENT 5
----------------------------------------
Diagnosis: NET des Pankreas mit Lymphknoten und Lebermetastasen (ED 2015)
CT bei unklaren abdominellen Beschwerden 06/2015: Tumor im Pankreas. G2 NET.
07/2015 CT staging Thorax/Abdomen: Primärtumor des Pankreas 20 x 40 x 30 mm. V.a. Lymphknotenmetastasen lokoregionär. V.a. Lebermetastasen in Segment VI und VIII.

06/2015 DOTATOC PET: starke Speicherung der Läsionen.
Relevant studies found: 20

  1. RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
     NCT ID: NCT00113360
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 32 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00113360

  2. A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
     NCT ID: NCT02402062
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 32 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT02402062

  3. Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
     NCT ID: NCT01010126
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 32 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT01010126

  4. Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
     NCT ID: NCT01169649
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 32 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT01169649

  5. Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
     NCT ID: NCT00454363
     Phase: PHASE2 | Status: COMPLETED
     Relevance: 32 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study; PHASE2 study
     URL: https://clinicaltrials.gov/study/NCT00454363

  6. Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
     NCT ID: NCT03375320
     Phase: PHASE3 | Status: ACTIVE_NOT_RECRUITING
     Relevance: 29 - NET condition match; Pancreatic NET match; Liver metastases match; Active study; PHASE3 study
     URL: https://clinicaltrials.gov/study/NCT03375320

  7. A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
     NCT ID: NCT00428220
     Phase: NA | Status: COMPLETED
     Relevance: 29 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study
     URL: https://clinicaltrials.gov/study/NCT00428220

  8. OPALINE : A Study Of Morbidity And Mortality At 2 Years
     NCT ID: NCT02264665
     Phase: N/A | Status: COMPLETED
     Relevance: 29 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study
     URL: https://clinicaltrials.gov/study/NCT02264665

  9. The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
     NCT ID: NCT02282059
     Phase: N/A | Status: COMPLETED
     Relevance: 29 - NET condition match; Pancreatic NET match; Liver metastases match; Completed study
     URL: https://clinicaltrials.gov/study/NCT02282059

  10. A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
     NCT ID: NCT02288377
     Phase: PHASE2 | Status: TERMINATED
     Relevance: 29 - NET condition match; Pancreatic NET match; Liver metastases match; PHASE2 study; 3 publications
     URL: https://clinicaltrials.gov/study/NCT02288377


================================================================================

